Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
20-valent pneumococcal conjugate vaccine
- Development stage
- Preclinical
- Lead developer
- WANTAI BioPharm
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
20-valent pneumococcal conjugate vaccine (PCV20) is a multivalent vaccine candidate developed by Shandong Kunli Biopharmaceutical for the prevention of pneumococcal disease, including pneumonia and invasive infections caused by *Streptococcus pneumoniae*. The vaccine utilizes conjugate technology, where capsular polysaccharides from 20 distinct serotypes of the bacteria are chemically linked to a carrier protein to enhance immunogenicity and induce a T-cell dependent immune response. This approach is designed to provide broad protection across various age groups, particularly infants and the elderly. As of the latest pipeline information, the program is in the IND-enabling phase of development.
- Other names
- 20价肺炎结合疫苗20-valent Pneumococcal Conjugate VaccinePCV20PCV-20PCV 20
02
Targets
SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)10A CPS (Streptococcus pneumoniae serotype 10A capsular polysaccharide)11A CPS (Streptococcus pneumoniae serotype 11A capsular polysaccharide)12F CPS (Streptococcus pneumoniae serotype 12F capsular polysaccharide)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)15B CPS (Streptococcus pneumoniae serotype 15B capsular polysaccharide)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS 22F (Streptococcus pneumoniae serotype 22F capsular polysaccharide)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)33F CPS (Streptococcus pneumoniae serotype 33F capsular polysaccharide)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on 20-valent pneumococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 20-valent pneumococcal conjugate vaccine.